DB
MNPR icon

Dmitry Balyasny’s Monopar Therapeutics MNPR Stock Holding History

Dmitry Balyasny’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5M Sell
134,543
-1,900
-1% -$118K 0.02% 963
2026
Q1 		$7.48M Buy
136,443
+104,536
+328% +$6.31M 0.01% 1167
2025
Q4 		$2.08M Buy
+31,907
New +$2.61M ﹤0.01% 1837
2025
Q2 		– Sell
-6,141
Closed -$224K – 3151
2025
Q1 		$224K Buy
+6,141
New +$221K ﹤0.01% 2550

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Dmitry Balyasny's MNPR Position: Q2 2026 in Review

Dmitry Balyasny reduced its Monopar Therapeutics (MNPR) stake by 1.4% in Q2 2026, selling an estimated $118K and leaving 134,543 shares worth $12.5M. The position accounts for 0.02% of the portfolio, ranked #963.

Dmitry Balyasny first reported a position in MNPR in Q1 2025 and has held it in 4 quarters since. 95 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Dmitry Balyasny held 134,543 shares of Monopar Therapeutics worth $12.5M as of Q2 2026.
  • Dmitry Balyasny sold 1,900 Monopar Therapeutics shares in Q2 2026, an estimated $118K.
  • Monopar Therapeutics made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #963 holding.
  • Dmitry Balyasny first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 95 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.